Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.

@article{Heijden2006PhaseIM,
  title={Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.},
  author={Antoine G. van der Heijden and Paula M. J. Moonen and Erik Bastiaan Cornel and Henk Vergunst and Theo M de Reijke and Erika van Boven and Evert J Barten and Rajiv Kumar Puri and Coenraad K van Kalken and Johannes Alfred Witjes},
  journal={The Journal of urology},
  year={2006},
  volume={176 4 Pt 1},
  pages={1349-53; discussion 1353}
}
PURPOSE We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. MATERIALS AND METHODS A total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. RESULTS One patient withdrew informed… CONTINUE READING